Featured Research

from universities, journals, and other organizations

Anti-androgen therapy for triple-negative breast cancer may benefit lower-androgen tumors

Date:
June 23, 2014
Source:
University of Colorado Denver
Summary:
Even triple negative breast cancers expressing very low levels of androgen receptor may benefit from anti-androgen therapy, researchers report. "This line of work is starting to change our thinking about who and when -- the timing and patient selection for anti-androgen receptor therapy in triple-negative breast cancer," says the study's first author.

Triple-negative breast cancers do not benefit from the targeted therapies that have greatly improved the survival of patients with other subtypes of breast cancer. But recent work shows that while these cancers lack estrogen receptors, progesterone receptors, and aren't driven by the gene HER2, up to a third of these tumors express the androgen receptor -- clinical trials are underway to inhibit the androgen receptor in these tumors in much the same way that the drug Tamoxifen inhibits estrogen receptor in estrogen-receptor-positive breast cancers. A new University of Colorado Cancer Center study being presented today at the Endocrine Society Annual Meeting shows that even triple negative breast cancers expressing very low levels of androgen receptor may benefit from this therapy.

"This line of work is starting to change our thinking about who and when -- the timing and patient selection for anti-androgen receptor therapy in triple-negative breast cancer," says Valerie Barton, the study's first author and PhD candidate in the lab of CU Cancer Center investigator Jennifer Richer, PhD.

Triple negative breast cancers were recently divided into further subtypes including a subtype with high androgen receptor expression (Lehmann, JCI 2011). However, other subtypes also express the androgen receptor. How would these different subtypes respond to anti-androgen receptor therapy? To find out, Barton and colleagues treated cell lines with the drug enzalutamide and with shRNAs designed to knock down androgen receptor levels. Interestingly, the drug enzalutamide is in wide use for prostate cancer, which tends to be driven by and dependent on androgen receptor.

Results showed that not only does anti-androgen receptor therapy reduce the ability of androgen-receptor-expressing triple-negative breast cancers to proliferate, migrate and invade, but for these cells, androgen receptor seems essential to survival. When Barton and colleagues blocked androgen receptor in these cells, the cells died.

But it was not only the high androgen-receptor-expressing cells that were affected.

"The study showed that androgen receptor has important roles in other subtypes of triple negative breast cancer as well," Barton says.

Across multiple triple-negative breast cancer subtypes, inhibiting the androgen receptor greatly increased apoptosis (programmed cell death), inhibited growth and increased necrosis by 60 percent in animal models.

"We're still early in the study of androgen receptor in breast cancer and already scientists are divvying up the disease to say, for example, that only the high AR expressing subtype should be treated with anti-androgen receptor therapies," Barton says. "But what we show is that even triple negative breast cancers with lower androgen receptor expression critically depend on the androgen receptor and may benefit from anti-androgen receptor therapy. Our results suggest that anti-androgen receptor therapy may benefit a larger percentage of triple negative breast cancers than previously thought."


Story Source:

The above story is based on materials provided by University of Colorado Denver. The original article was written by Garth Sundem. Note: Materials may be edited for content and length.


Cite This Page:

University of Colorado Denver. "Anti-androgen therapy for triple-negative breast cancer may benefit lower-androgen tumors." ScienceDaily. ScienceDaily, 23 June 2014. <www.sciencedaily.com/releases/2014/06/140623121006.htm>.
University of Colorado Denver. (2014, June 23). Anti-androgen therapy for triple-negative breast cancer may benefit lower-androgen tumors. ScienceDaily. Retrieved August 28, 2014 from www.sciencedaily.com/releases/2014/06/140623121006.htm
University of Colorado Denver. "Anti-androgen therapy for triple-negative breast cancer may benefit lower-androgen tumors." ScienceDaily. www.sciencedaily.com/releases/2014/06/140623121006.htm (accessed August 28, 2014).

Share This




More Health & Medicine News

Thursday, August 28, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Mini Pacemaker Has No Wires

Mini Pacemaker Has No Wires

Ivanhoe (Aug. 27, 2014) Cardiac experts are testing a new experimental device designed to eliminate major surgery and still keep the heart on track. Video provided by Ivanhoe
Powered by NewsLook.com
After Cancer: Rebuilding Breasts With Fat

After Cancer: Rebuilding Breasts With Fat

Ivanhoe (Aug. 27, 2014) More than 269 million women are diagnosed with breast cancer each year. Many of them will need surgery and radiation, but there’s a new simple way to reconstruct tissue using a patient’s own fat. Video provided by Ivanhoe
Powered by NewsLook.com
Blood Clots in Kids

Blood Clots in Kids

Ivanhoe (Aug. 27, 2014) Every year, up to 200,000 Americans die from a blood clot that travels to their lungs. You’ve heard about clots in adults, but new research shows kids can get them too. Video provided by Ivanhoe
Powered by NewsLook.com
Radio Waves Knock out Knee Pain

Radio Waves Knock out Knee Pain

Ivanhoe (Aug. 27, 2014) Doctors have used radio frequency ablation or RFA to reduce neck and back pain for years. But now, that same technique is providing longer-term relief for patients with severe knee pain. Video provided by Ivanhoe
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins